{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-031010","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.169481+00:00","generated_at":"2026-06-05T03:20:11.003614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights","bullets":["Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).","FY 2023 net loss $25.1M ($0.14/sh) vs $58.6M in 2022; revenue $116.9M, TAVALISSE $93.7M (+24% YoY).","Acquired U.S. rights to GAVRETO (pralsetinib) for RET+ NSCLC/thyroid cancer; expects sales recognition in Q3 2024.","Q4 TAVALISSE bottles shipped to patients/clinics: 2,463; REZLIDHIA bottles: 278 direct, QoQ growth 47%.","Cash & short-term investments $56.9M at Dec 31, 2023, vs $58.2M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-031010","json":"https://secwatch.observer/filing/0001104659-24-031010.json","markdown":"https://secwatch.observer/filing/0001104659-24-031010.md","text":"https://secwatch.observer/filing/0001104659-24-031010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/0001104659-24-031010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/tm247928d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:20:11.003614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bc62df6de2094aad9d20756cc78db414eb47e46","claim":"RIGEL PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 5, 2024, Rigel Pharmaceuticals, Inc. (“ Rigel ”) announced certain financial results for its fourth quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924031010/0001104659-24-031010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}